Zuclopenthixol

from Wikipedia, the free encyclopedia
Structural formula
Structure of zuclopenthixol
General
Non-proprietary name Zuclopenthixol
other names
  • ( Z ) -2- [4- [3- (2-chlorothioxanthen-9-ylidene) propyl] piperazin-yl] ethanol ( IUPAC )
  • cis -2- {4- [3- (2-chlorothioxanthen-9-ylidene) propyl] piperazin-1-yl} ethanol
Molecular formula C 22 H 25 ClN 2 OS
External identifiers / databases
CAS number 53772-83-1
ECHA InfoCard 100.053.398
PubChem 5311507
ChemSpider 4470984
DrugBank DB01624
Wikidata Q228143
Drug information
ATC code

N05 AF05

Drug class

Antipsychotic

properties
Molar mass 400.97 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances
07 - Warning

Caution

H and P phrases H: 302
P: ?
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Zuclopenthixol is a heterocyclic organic- chemical compound from the group of thioxanthenes . The drug is used to treat psychosis . Zuclopenthixol is a dopamine - and serotonin receptor - antagonist . Zuclopenthixol was first marketed as Clopixol in 1986 by Lundbeck as an effective component of a drug .

Clinical information

Approved areas of application

Zuclopenthixol is approved for the treatment of acute and chronic schizophrenia , mania , psychomotor agitation and aggressive behavior in the case of intellectual disabilities or dementia .

unwanted effects

The following undesirable effects are very common: accommodation disorders , urge to move, dry mouth, tiredness (up to 80% at the beginning of treatment), muscle stiffness , Parkinson's disease , torticollis, dizziness, sitting restlessness , tremors and throat syndrome .

Loss of appetite, eye cramps, nausea, depression, diarrhea, dystonia , vomiting , cardiac conduction disorders , photosensitivity , skin rash, headache, menstrual disorders , hives , increased reflexes or nausea occur frequently .

History

Zuclopenthixol was developed by the Danish company Lundbeck. It is the pure ( Z ) isomer (synonym: cis isomer) of the ( EZ ) isomer mixture (synonym: cis , trans isomer mixture) previously developed by Lundbeck, Clopenthixol , which was first marketed in 1986. Lundbeck licensed clopenthixol to Bayer for Germany . In 2000 Bayer withdrew Clopenthixol (a mixture of substances) from the market and replaced it with Zuclopenthixol.

Trade names and dosage forms

The drug Zuclopenthixol is sold in three different salt and ester forms:

All three salt and ester forms are available in Germany, Austria and Switzerland, but are sold under different trade names: Ciatyl-Z in Germany ( Bayer ), Cisordinol in Austria (Lundbeck) and Clopixol in Switzerland (Lundbeck).

See also

Individual evidence

  1. ↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of zuclopenthixol in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), retrieved on June 24, 2020, is reproduced from a self-classification by the distributor .
  2. ↑ E. Coutinho, M. Fenton, S. Quraishi: Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000; CD001164. PMID 10796607 .
  3. ^ RC Gibson, M. Fenton, ES Coutinho, C. Campbell: Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev. 2004; CD000525. PMID 15266432 .
  4. ↑ A. Kumar, D. Strech: Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2005; CD005474. PMID 16235403 .
  5. ↑ MG Izmeth, SY Khan, DI Kumarajeewa et al .: Zuclopenthixol decanoate in the management of behavioral disorders in mentally handicapped patients. In: Pharmatherapeutica. 5, 1988, pp. 217-227. PMID 2902642 .

Web links